Corcoran Andrea 4

What Happened Andrea Corcoran, Atea Pharmaceuticals’ Chief Financial Officer (also Executive VP, Legal and Secretary), exercised options on March 11, 2026 to acquire a total of 120,000 shares. The filing shows two derivative exercises: 60,000 shares at an exercise price of $1.24 (total cash paid $74,400) and 60,000 shares reported with a $0 exercise price (no cash reported). No sales of the shares were reported in this filing, so the transaction is an acquisition of stock via option exercise.

Key Details

• Transaction date: 2026-03-11 (reported on Form 4 filed 2026-03-13). Filing appears timely for the reported transaction.
• Transaction codes: M = Option exercise/conversion.
• Lots: 60,000 shares acquired at $1.24 (cash $74,400); 60,000 shares acquired at $0 (no cash reported).
• Shares owned after transaction: Not specified in the disclosed excerpt of the filing.
• Footnote: F1 — "The option is fully vested and exercisable."
• Remarks list Corcoran’s roles: Chief Financial Officer; Executive Vice President, Legal and Secretary.

Context This was an exercise of derivative awards (options/other convertible instruments), not an open-market purchase or sale. Because there was no immediate sale reported, the insider increased her shareholdings. Exercises can reflect routine option vesting or planned compensation actions; the filing itself does not state motivation. The presence of a $0-priced lot may reflect a non-cash conversion or different award terms; the filing notes the option is fully vested and exercisable.